Sodium iodide symporter (NIS)-based radionuclide therapy provides an effective means of treating malignant tumors. However, it is sometimes inadequate because of limited effects on radio-resistant tumors, and thus, combination therapies with other therapeutic options have been requested to enhance its efficacy. Human telomerase reverse transcriptase (hTERT) has been reported to be involved in the progression of most cancers and also been viewed as a good candidate for targeting tumor. Application of TERTspecific radionuclide therapies using NIS gene transfer have been reported to treat TERT-positive tumors, but this approach only demonstrated tumor regression rather than eradication. As inhibiting TERT expression by introducing the hTERT-specific shRNA (siTERT) has been suggested as a therapeutic option, we investigated the complementary role of siTERT treatment after the TERTspecific I-131 therapy and its possibility as a novel anticancer therapeutic strategy. Retroviruses containing TERT promoter/NIS for TERT specific Radionuclide therapy and siTERT for TERT targeting antisense therapy were produced. Hep3B cells expressing TERT specific NIS (Hep3B-TERT/NIS) were xenografted into nude mouse and visualized with micro-SPECT/CT for monitoring NIS activity. The levels of hTERT mRNA, protein and its activity were confirmed by RT-PCR, Western blotting and Telomerase repeat amplification protocol assay. Cell proliferation was monitored by MTT assay and induced apoptosis was confirmed by Annexin-V-PI staining. Therapeutic effects of I-131 and/or siTERT were evaluated by clonogenic assay and mouse tumor model. Reduction of hTERT mRNA, protein and TERT activity by siTERT were observed in Hep3B-TERT/NIS cells. The viabilities of the infected cells were significantly decreased to 50% versus siScramble treated controls. The early apoptotic cell population was increased by siTERT. The survival rates of cells treated with siTERT or I-131 alone were 72.4 ± 7.6% and 56.2 ± 5.2%, respectively. However, the survival rate of cells treated with I-131 and siTERT were decreased to 22.1 ± 2.8%. From mouse xenograft model, we also found that the siTERT gene therapy showed synergism to the radioiodine therapy for reducing tumor growth in vivo. Our Results suggested that complementary siTERT gene therapy offers a novel strategy of cancer therapy to improve the therapeutic efficacy of TERT-specific I-131.
Introduction
Sodium iodide symporter (NIS)-based radionuclide therapy provides an effective means of treating malignant tumors. However, it is sometimes inadequate and its effects on radio-resistant tumors are limited, and thus, combination therapies with other therapeutic modalities have been examined to enhance its therapeutic efficacy. 1, 2 Telomeres are chromosomal regions that consist of long 5 0 -TTAGGG-3 0 nucleotide repeats and telomere binding protein complex. 3 In eukaryotic chromosomal DNA, telomeres are shortened each time a cell divides until they reach critical lengths that trigger cell death. 4 On the other hand, most cancer cells demonstrate high telomerase expression and the majority of human cancers prevent telomere erosion by telomerase. Telomerase activation by human telomerase reverse transcriptase (hTERT) has been described as a critical step during cancer progression, and the telomerase activation is also related to tumor cell radioresistance. 5 Accordingly, the suppression of hTERT might provide a means of attacking tumor viability.
In a previous study, 6 we performed tumor-targeted radionuclide therapy in 5 mm TERT-NIS expressing cells. We observed that tumor growth was reduced after TERT targeted I-131 therapy, but tumor growth was still continued despite of initial tumor growth retardation after I-131 therapy. Thus, a new approach was required to enhance therapeutic effect of TERT-specific I-131 therapy.
RNA interference (RNAi) provides a means of gene silencing, and several researchers have identified possible uses for RNAi-based antisense oligonucleotides for the treatment of cancer. 7 Recently, lentiviral and retroviral vector-based RNAi systems have been developed to enhance and stabilize the expression of siRNA. 8 Interestingly, efficient telomerase inhibition using this system also has been reported. 9, 10 In the present study, we engineered a retrovirus carrying TERT-specific shRNA (siTERT) to induce the stable inhibition of telomerase. We utilized a combination of hNIS-based I-131 therapy using the TERT promoter-NIS system to allow tumor-specific delivery of radionuclide and retrovirus carrying siTERT to inhibit hTERT expression, monitoring the synergistic effect of radiotherapy with siTERT in vitro and in vivo.
Materials and methods

Cell lines
Hep3B human hepatoma cells (TERT positive) and U2-OS human osteosarcoma cells (TERT positive) were obtained from the Korean Cell Line Bank. Hep3B cell lines were incubated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and a 1% antibiotic/antimycotic mix. U2-OS cells were maintained in McCoy's 5A medium with 15% fetal bovine serum.
Hep3B cells containing the 5 mm TERT promoter/NIS gene (Hep3B-TERT/NIS) have been established 6 using retroviral transduction with pMSCV-TERT/NIS (Figure 1b) . Retrovirus (pMSCV-TERT/NIS) was generated using a modification of the manufacturer's instructions using a Retro-X Universal packaging system (BD Biosciences Clontech, Palo Alto, CA) and selection was performed by 1.5 mg ml À1 puromycin in complete Dulbecco's modified Eagle's medium over 2 weeks. 6 In vitro radioiodine uptake assay Hep3B-TERT/NIS were plated into 24-well plates at 1.5 Â 10 5 cells per well and incubated for 24 h. Cells were then washed with Hanks balanced salt solution (HBSS) and incubate with 500 ml of HBSS containing 0.5% bovine siTERT with TERT-specific I-131 therapy S Kim et al serum albumin, 10 mmol l À1 of 2-(4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic acid-NaOH (pH 7.4), 10 mM of NaI (specific activity 740 mBq mmol À1 ) and 3.7 kBq (0.1 mCi) carrier-free Na(I-125) at 37 1C for 30 min. Cells were then washed twice very quickly with 2 ml of iodinefree ice-cold HBSS buffer. 0.2% SDS was used to detach cells and radioactivities were measured using a gamma counter (Cobra II, Canberra Packard, Meriden, CT).
Evaluation of hTERT-targeted NIS expression by in vivo microSPECT/CT Hep3B and Hep3B-TERT/NIS cells were transplanted into the right and left flanks of mice, respectively. Mice were anesthetized by isofluorane inhalation 1-hour after injecting 72 MBq (1 mCi) of Tc-99 m intraperitoneally. The mice were then fixed individually in a rotating animal holder, and a CT scan was performed using the following settings; voltage 70 kV, current 400 mA and exposure time 200 ms. SPECT imaging was performed using a pinhole collimator. The SPECT/CT images were reconstructed and fused using Inveon Acquisition Workplace software (Siemens, Knoxville, TN). All images were acquired using an Inveon Multimodality Scanner System (Siemens).
Construction of the retroviral shRNA expression vector Viral vectors for siTERT and siScramble were constructed using knockout inducible RNAi systems (Clontech, Palo Alto, CA), according to the manufacturer's instructions. Briefly, to construct telomerase-specific shRNA or scramble shRNA expressing viral vectors, target sequences were obtained, 8, 11 and then the sequences of the DNA pair for cloning were designed using shRNA sequence designer (http://bioinfo2.clontech.com/rnaidesigner) and synthesized. Two single-strand DNA encoding two linker with restriction site, the target sequences, terminator and a hairpin loop sequences were synthesized. Annealed fragments were cloned into the BamH1 and EcoR1 sites of an RNAi-Ready pSIREN-RetroQ-Tet vector. The structure and the target sequences of shRNA for scramble and siTERT were illustrated in the Figure 2a .
Retrovirus production
In brief, 293FT cells were cotransfected with 5 mg of generated retroviral vector, 5 mg of pcDNA3, gag-pol vector and 5 mg of envelop vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Supernatant was collected at 72 h post-transfection and concentrated using an Amicon Ultra 100 K Filter (Millipore, Bedford, MA), and filtered through a 0.45 mm polyvinylidene difluoride filter (Millipore). For the animal study, this supernatant was centrifuged at 25 000 rpm for 90 min at 4 1C and the pellet so obtained was suspended in PBS. The viral supernatant was titered in NIH3T3 cells, according to the manufacturer's instructions (BD Biosciences Clontech). Virus was stored at À80 1C until required.
RT-PCR
After virus infection, total RNA was isolated from cells using TRIzol reagent (Invitrogen) and quantified according to the manufacturer's instructions. Total RNA was reverse transcribed in a final volume of 20 ml containing 1 ml oligo(dT), 4 ml of 5 Â first-strand buffer, 2 ml of 0.1 M dithiothreitol and 1 ml of 10mM deoxyribonucleoside triphosphate mix containing 1 ml of Moloney Murine Leukemia Virus reverse transcriptase (Invitrogen).
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AACTGTGCCCATCTA-3
0 and reverse, 5 0 CTAGAAGC ATTTGCGGTGGACGATGGAGGG-3 0 . PCR products were detected by SYBR Green staining.
Western blot
Cells were washed with PBS and mechanically detached with a scrapper. They were then centrifuged and extracted using RIPA buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA pH 8.0, 0.5% NP-40) containing a protease inhibitor cocktail (Roche, Nutley, NJ) for 90 min on ice and centrifuged at 13 000 rpm for 30 min at 4 1C. Supernatants were collected and protein amounts were determined using the BCA protein assay (Pierce, Rockford, IL). Total protein of 20 mg aliquots was separated in bis-Tris-HCl buffered 4-12% gradient polyacrylamide gels (Invitrogen). Gels were blotted onto polyvinylidene difluoride membranes (Millipore, Watford, UK) and blocked in 3% bovine serum albumin in TBS-T (20 mM Tris, 137 mM NaCl and 0.1% Tween 20) and probed overnight at 4 1C with primary antibodies. The primary antibodies were used as follows: hTERT (Abcam, Cambridge, MA) and a-tubulin (Sigma, St Louis, MO). Membranes treated with antibodies were then incubated with secondary antibodies against anti-rabbit or anti-mouse IgG (InvitrogenMolecular Probes, Eugene, OR). Blotted proteins were visualized using enhanced ECL reagents (Roche).
Detection of telomerase activity using a telomerase repeat amplification protocol (TRAP) assay TRAP activity was measured using TRAPeze telomerase detection kits (Chemicon International, Temecula, CA), as previously described. 10 Cells were harvested, washed and resuspended in 200 ml of 1 Â CHAP lysis buffer provided in the kit. Lysates were then aliquoted into microcentrifuge tubes and stored at À80 1C until required. Aliquotes of cells were processed with or without heat inactivation at 85 1C for 10 min, and then subjected to three-step PCR (20 cycles of 94 1C for 30 s, 59 1C for 30 s and 72 1C for 1 min) in a thermocycler. The PCR products were resolved in 10% non-denaturing polyacrylamide gels in 0.5 Â TBE buffer. Gels were stained with SYBR green and visualized using a Maestro in vivo Imaging System (CRi, Woburn, MA).
Estimating toxicity of the siTERT using an MTT assay and Annexin-V staining H5TN cells were seeded in decapitates, in a flat-bottomed 96-well plate, and infected with virus at multiplicity of infection of 0.025 cfu per cell. MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2Htetrazoliumbromide, 2 mg ml À1 in PBS; Amresco, Solon, OH) was added to wells at 3 day after virus infection and incubated for 4 h. After removing MTT, formazan was resuspended in 200 ml of DMSO. Absorbances were measured at 560 nm.
Apoptosis assays by ELISA reader Proportions of cells undergoing apoptosis were determined using an Annexin-V-FITC Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA). After virus infection, cells was washed with cold PBS and resuspended in 1 Â binding buffer at a density of 1 Â 10 6 cells per ml. The cells were stained with both Annexin-V-FITC and PI (5 ml of each per sample) and then samples were analyzed using a Becton Dickinson FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA).
In vitro measurements of the combined therapeutic effects of siTERT and I-131 by clonogenic assay Before 1 day of assay, Hep3B-TERT/NIS cells were plated in 75-cm 2 flasks. Cells were washed with HBSS for once and incubated with HBSS containing 37 MBq of 131 I and 20 mM NaI for 7 h at 37 1C. They were then washed twice with HBSS and once with PBS, and infected with siTERT for 72 h at multiplicity of infection of 0.12 cfu per cell. After infection, the cells were seeded in six-well plates (at a cell density of 1000 cells per well) and incubated until colonies were visible. These were stained using crystal violet (0.5 g of crystal violet solution, 25 ml of 40% formaldehyde, 50 ml of ethanol and 175 ml of water) and counted. The results are expressed as percentage of colonies as compared with non-treated cells.
In vivo measurements of the combined therapeutic effects of siTERT and I-131 in a nude mouse model Hep3B-TERT/NIS cells were subcutaneously injected into the right flanks of 5-week-old nude mice. When tumors reached a diameter of 10 mm, mice were separated into four groups (the PBS group, the siTERT group, the I-131 group and the I-131 þ siTERT group). To induce the accumulation of I-131 in tumor cells, mice were maintained on a low-iodide diet with T4 supplementation in water for 1 week. And then 111 MBq of I-131 was injected intraperitoneally. After 2 days of I-131 treatment, siTERT was intratumorally injected twice at a viral titer of 8 Â 10 6 cfu per mouse with a 3-day interval. Tumor sizes were measured using a caliper every 3 days for 20 days. Tumor volumes were calculated as previously described. 6 Histopathology and immunofluorescence staining of tumor tissue with TERT antibody After I-131 and/or siTERT treatment in vivo, Hep3B-TERT/NIS tumors were removed and preserved in 10% formalin solution (Sigma) for 24 h. Tumors were embedded using paraffin and sectioned to 4-mm slice. Then tumor sections were incubated for 24 h at 65 1C. For deparaffinization, these slices were incubated in 0.3% hydrogen peroxide in methanol, washed twice in distilled water for 5 min and rinsed with PBS. The slices were then incubated in 0.5% Triton X-100 in PBS and washed with PBS for 5 min. Finally, these slices were stained using hematoxylin and eosin.
For immunofluorescence staining, the blocking step was followed with 1% normal horse serum for 30 min at room temperature and the slices were incubated with a mouse monoclonal anti-human TERT antibody (Abcam). After three times washing with PBS, the level of TERT expression was detected with Alexa Fluor 488 goat antirabbit IgG (Invitrogen) and the signal was analyzed using Zeiss LSM510 META confocal imaging system (Carl Zeiss, Oberkochen, Germany).
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Data analysis
All data are presented as means ± s.d. Statistical significances were determined using the Student's t-test and P-values of o0.05 were considered statistically significant.
Results
TERT-specific radioiodine uptake and micro-SPECT/CT imaging of Hep3B-TERT/NIS tumors For validation of Hep3B-TERT/NIS cells as a good model system for TERT-specific radioiodine therapy, we confirmed the specific expression of TERT mRNA in Hep3B cells (Figure 1a) . As the TERT promoter was designed by modification of 5 mm TERT promoter, 6, 12 the expression of NIS was expected to be induced in the TERT-positive Hep3B cells. Retroviral pMSCV-TERT/ NIS vector (Figure 1b ) allowed stable transduction of TERT-specific NIS expression in the TERT-positive Hep3B cells. Radioiodine uptake of Hep3B-TERT/NIS was 4.2-6.3 times higher than that of Hep3B (Figure 1c) . Moreover, TERT-negative U2-OS cells transfected with virus having CMV promoter showed similar radioiodine uptake with TERT-positive Hep3B cells, and cells with promoter-less NIS showed no radioiodine uptake (data not shown). These Results indicated that our Hep3B-TERT/NIS cell system for radioiodine therapy is specifically activated in TERT-positive Hep3B cell in response to 5 mm TERT promoter. The TERT-specific expression of hNIS by TERT promoter in vivo was also confirmed using nuclear imaging modality. Tumor-bearing mice were treated with 1 mCi of Tc-99 m and monitored with micro-SPECT/CT. Hep3B-TERT/NIS tumors showed high Tc-99 m uptakes, whereas Hep3B tumors did not. Physiological uptake was also observed in thyroid, stomach and urine as usual (Figure 1d ).
Downregulation of hTERT expression and its activity by siTERT
As shown in Figure 2a , two single-stranded DNAs with hairpin loop structure for shTERT were designed to generate siTERT viruses. For monitoring successful interference of hTERT, the level of hTERT was measured after siTERT virus infection (Figure 2b ). Expression of hTERT mRNA diminished to barely detectable levels in cells infected with siTERT virus as compared with siScramble virus infected cells. As was expected, cells treated with siTERT virus expressed little hTERT protein by western blotting. The effect of siTERT virus on telomerase activity was also examined by TRAP assay. TRAP assay showed that telomerase activity was completely blocked by siTERT, but that it was unaffected in non-infected cells (Figure 2c ). These results indicated that our siTERT system was successfully operated to inhibit the hTERT expression.
In vitro inhibition of proliferation and the induction of apoptosis by siTERT
The proliferation of Hep3B-TERT/NIS cells treated with siTERT virus was significantly inhibited at 3 days after virus infection as compared with siScramble virus infected cells (Figure 3a ), but the cell proliferation of TERTnegative U2-OS cells was not influenced by siTERT virus infection (Figure 3b ). The percentage of early apoptotic cells (Annexin-V þ /PIÀ) in Hep3B-TERT/NIS was significantly higher for siTERT-infected cells than for siScramble infected cells (Figure 3c) . The early apoptotic cell proportions of siTERT and siScramble infected cells were 13.9 ± 2.9% and 5.4 ± 3.8%, respectively. These results suggested that siTERT treatment could be used as an efficient tumor therapy inducing apoptotic response.
In vitro tumor cell cytotoxicity of combination therapy In vitro clonogenic assay was performed to evaluate the effect of combined therapy with siTERT and I-131. In clonogenic assays, the survival rates of Hep3B-TERT/ NIS cells treated with siTERT or I-131 alone were 72.4 ± 7.6% and 56.2 ± 5.2%, respectively. However, the survival rate of cells treated with I-131 plus siTERT was dramatically reduced to 22.1±2.8% (Figure 3d ). This result demonstrated that the combination therapy of siTERT and radioiodine could synergistically reduce tumor cells survival at the cellular level. Figure 3 Reduced proliferation, cytotoxicity and apoptosis by siTERT in vitro. (a) The proliferations of Hep3B-TERT/NIS cells were determined using MTT assays at 3 days after siScramble or siTERT virus infection (Po0.01; two-tailed t-test; n ¼ 5 in each group). (b) The proliferations of TERT-negative U2-OS cells were determined using MTT assays at 3 days after siScramble or siTERT virus infection (Po0.01; two-tailed t-test; n ¼ 5 in each group). (c) Apoptosis was monitored by Annexin-V-FITC/PI flow cytometry (Po0.05; two-tailed t-test; n ¼ 3 in each group). (d) The cytotoxic effects of siTERT on Hep3B-TERT/NIS cells were quantified clonogenic assays (Po0.01; two-tailed t-test; n ¼ 6 in each group). For evaluating the complementary effect of siTERT on I-131 therapy, Hep3B-TERT/NIS cells were treated with 37 MBq of I-131 and after 7 h of incubation cells were infected with siTERT virus at multiplicity of infection of 0.12 cfu per cell. All data are representative of at least three independent experiments (Po0.01; two-tailed t-test; n ¼ 6 in each group).
In vivo synergistic effect of combination therapy To evaluate the in vivo therapeutic effect of combined therapy with radioiodine therapy and retrovirus-induced hTERT gene silencing we monitored tumor volumes. The growth of tumors treated with PBS alone continued up to 576.3 ± 96.4% of initial tumor volumes (measured 20 days after Hep3B-TERT/NIS cell implantation). The tumor volumes of animals treated with siTERT or I-131 alone were 457.9 ± 139.2 or 171.9 ± 181.9% of initial tumor volume. Although tumor growth retardation was observed in the I-131 group, tumor volumes continuously increased after 2 weeks, and the siTERT group showed only a small therapeutic effect. However, the I-131 þ siTERT group demonstrated a synergistic effect and tumor volumes decreased to 61.4 ± 19.0% of initial volumes (Figure 4) .
In vivo specificity of siTERT treatment on TERT knockdown To monitor the specificity of siTERT on hTERT expression in the tumor tissue, we isolated the implanted tumor tissues to perform immunofluorescence assay. Treatment of siTERT showed successful inhibition of telomerase expression in tumor tissue compared with the control group ( Figure 5) . Interestingly, the hTERT expression was somewhat increased by I-131 treatment in the tissue, but combined therapy with siTERT successfully inhibited hTERT expression to the level of control. This result indicated that the treatments of siTERT were specifically downregulated the TERT expression in vivo tumor tissue.
Discussion
Surgery, chemotherapy and radiotherapy are widely used types of cancer therapy, but sometimes results are less than satisfactory. Recently, targeted gene therapy was suggested as a promising new method. However, effective tumor targeting remains a challenge and many researchers are trying to identify better targeting systems. Telomerase could be a suitable target, because telomerase expression is observed in most cancer cells, but not in normal cells, and telomerase has an important role in cancer progression. 13 Furthermore, induces the accumulation of therapeutic radionuclides (I-131 and Re-188) and imaging radionuclides (I-123 and Tc-99 m) in target cells. 14 We established a 5-mm TERT-NIS system to provide TERT-specific radionuclide therapy and to demonstrate the possibilities of molecular imaging and radioiodine gene therapy. 10 Though we observed that tumor growth was reduced after TERT-targeted I-131 therapy, tumor growth was still continued despite of initial tumor growth retardation after I-131 therapy. Thus, a new approach was required to enhance therapeutic effect of TERT-specific I-131 therapy.
Telomerase activity is related to radiation-induced DNA damage. Telomerase participates in the DNA repair process, 15 and its activation may also affect chromosome healing. 12 Thus, radiation exposure can increase telomerase activity in tumor cells and induce DNA damage resulting in the killing of tumor cells. However, after radiation therapy, some radiation-resistant cells can appear, and these can cause tumor recurrence and poor outcomes. 3 We tried to inhibit telomerase activity after radionuclide gene therapy, because previously we found that radionuclide gene therapy had an inadequate effect on tumor growth. 10 One recent study found that hTERT promoter activity was increased in radiation-resistant laryngeal squamous cell carcinoma, and examined the effects of suicidal gene (hTERTp-HRP/IAA) therapy using hTERT promoter plus radiotherapy and they showed efficient tumor specific cytotoxicity of prodrug IAA in radiation-resistant human squamous cell carcinoma. 16 From immunofluorescence staining of xenografted tumor tissue, we could also find that the level of TERT expression was elevated in the I-131 tumor. This indicates that these radiation-resistant tumor cells can be a possible reason for tumor regrowth. Therefore, telomerase inhibition can be an option for eradicates radiation-resistant tumors. Telomerase inhibition therapy has been tried using several approaches, such as, using telomerase specific inhibitors (BIBR1532 or GRN163L), ribozymemediated telomerase inhibition and RNAi-based telomerase inhibition. 8, [17] [18] [19] [20] [21] In the present study, we developed a retrovirus carrying TERT-specific siRNA system to downregulate hTERT expression after TERT-specific radioiodine therapy. We found that our siTERT virus system inhibited tumor cell proliferation and had apoptotic effects on infected cells in vitro. We also found that tumor cells survived after radionuclide treatment are susceptible to the downregulation of TERT mRNA. The survival rates of cells treated with I-131 plus siTERT decreased to 22%, whereas the survival rates of individual treatment, siTERT or I-131, were 56.2±5.2% and 72.4±7.6%, respectively. Furthermore, hNIS-based I-131 therapy plus siTERT was found to have a synergistic effect in an animal tumor model.
The devised method has the advantage that siTERT therapy follows I-131 therapy. Thus, radiation-resistant cells after I-131 therapy might be effectively eradicated by subsequent siTERT therapy because of the enhanced expression of hTERT in radio-resistant cells. In the present study, the rate of tumor growth in the I-131 therapy group was retarded compared with PBS or siTERT treated group. However, the tumor volumes of the I-131 therapy group were continuously larger than that of its initial volumes by up to 20 days after treatment. The combined therapy of I-131 plus siTERT showed improved therapeutic effect demonstrating the tumor volumes were continuously smaller than initial volumes.
However, this study has several limitations. First, initially, siTERT was injected intratumorally and this resulted in its heterogeneous distribution in tumor tissue. Accordingly, the therapeutic effect of siTERT seems to be underestimated in vivo. Second, the doses and frequencies of I-131 and/or siTERT treatment are likely to influence therapeutic results, and the type of vector system used to deliver siTERT could be also involved. Further experiments are required to be analyzed the unique characteristics of surviving tumor cells after combined therapy to eradicate residual tumor cells after I-131 plus siTERT combined therapy. Repeated challenge of siTERT after one cycle of this therapy (3 weeks in this case) can be possible option.
As some serious adverse events following retrovirusmediated gene therapy have occurred, 22 clinical relevance of retroviral system for gene delivery is still controversial. However, transduction of a suicidal gene under the control of an inducible promoter could be a good safety features for retrovirus-mediated gene therapy. Also our system has safety feature using the conditional expression of NIS triggered only in the cells with higher level of TERT. Our retroviral construct of pMSCV-TERT/NIS contains TERT-specific promoter, which could express exogenous NIS only in the tumor cells with higher level of TERT. After radiation therapy, most of the tumor cells containing foreign gene, pMSCV-TERT/NIS, would be dead because of radioiodine uptake and we focused on the residual radiation-resistant tumor cells. Additionally, we applied siTERT virus to the targeted local administration and this will increase the overall safety of our retroviral systems. However, an ultimate solution to this problem will be in re-engineering retroviral vectors so that the retroviral insertion takes place only at the desired specific sites of the host-cell chromosome to prevent retrovirusmediated oncogenesis. Though this is a technically demanding task, the development of retroviral vectors system for targeted insertion by homologous recombination is possible and this could be our next step to develop.
To summary, both I-131 therapy using the pMSCV-TERT/NIS system and siTERT therapy were found to cause tumor cell death, but in combination, they showed obvious synergistic effects in vitro and in vivo. Our results indicate that residual tumor cells express higher level of TERT after TERT-specific I-131 therapy and siTERT can effectively eradicate surviving tumor cells after radioiodine therapy. We suggest that this combination therapy based on the TERT-specific radioiodine therapy siTERT with TERT-specific I-131 therapy S Kim et al
